The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 2024
Filed:
Jun. 06, 2017
Applicant:
Modernatx, Inc, Cambridge, MA (US);
Inventors:
Leif Karlsson Parinder, Mölndal, SE;
Regina Desirée Fritsche Danielson, Mölndal, SE;
Kenny Mikael Hansson, Mölndal, SE;
Li Ming Gan, Mölndal, SE;
Jonathan Clarke, Stockholm, SE;
Ann-Charlotte Eva Egnell, Mölndal, SE;
Kenneth Randall Chien, Stockholm, SE;
Assignee:
ModernaTX, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/515 (2006.01); A61K 38/18 (2006.01); A61K 31/712 (2006.01); A61P 9/10 (2006.01); A61P 17/02 (2006.01); A61P 13/12 (2006.01); A61P 9/04 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01);
U.S. Cl.
CPC ...
C07K 14/515 (2013.01); A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 31/712 (2013.01); A61K 38/1866 (2013.01); A61K 47/12 (2013.01); A61P 9/10 (2018.01); A61P 17/02 (2018.01);
Abstract
The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.